Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
98% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SGEN' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Equity to Asset 0.47
SGEN's Equity to Asset is ranked lower than
72% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SGEN: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
SGEN' s 10-Year Equity to Asset Range
Min: 0.36  Med: 0.58 Max: 0.96
Current: 0.47
0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
97% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 13.50
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -27.52
SGEN's Operating margin (%) is ranked higher than
58% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. SGEN: -27.52 )
Ranked among companies with meaningful Operating margin (%) only.
SGEN' s 10-Year Operating margin (%) Range
Min: -9958.59  Med: -260.49 Max: -23.35
Current: -27.52
-9958.59
-23.35
Net-margin (%) -27.12
SGEN's Net-margin (%) is ranked higher than
57% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. SGEN: -27.12 )
Ranked among companies with meaningful Net-margin (%) only.
SGEN' s 10-Year Net-margin (%) Range
Min: -7917.17  Med: -242.65 Max: -23.22
Current: -27.12
-7917.17
-23.22
ROE (%) -36.99
SGEN's ROE (%) is ranked lower than
55% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. SGEN: -36.99 )
Ranked among companies with meaningful ROE (%) only.
SGEN' s 10-Year ROE (%) Range
Min: -128.57  Med: -43.57 Max: -24.17
Current: -36.99
-128.57
-24.17
ROA (%) -17.50
SGEN's ROA (%) is ranked higher than
58% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. SGEN: -17.50 )
Ranked among companies with meaningful ROA (%) only.
SGEN' s 10-Year ROA (%) Range
Min: -50.86  Med: -34.04 Max: -12
Current: -17.5
-50.86
-12
ROC (Joel Greenblatt) (%) -190.36
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. SGEN: -190.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -903.49  Med: -498.01 Max: -178.02
Current: -190.36
-903.49
-178.02
Revenue Growth (3Y)(%) 40.30
SGEN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SGEN: 40.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.3  Med: 39.90 Max: 157.1
Current: 40.3
7.3
157.1
EBITDA Growth (3Y)(%) -24.70
SGEN's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. SGEN: -24.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.2  Med: -1.65 Max: 18
Current: -24.7
-30.2
18
EPS Growth (3Y)(%) -22.70
SGEN's EPS Growth (3Y)(%) is ranked lower than
70% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SGEN: -22.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -34  Med: -4.65 Max: 27.9
Current: -22.7
-34
27.9
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SGEN Guru Trades in Q3 2014

Ray Dalio 6,140 sh (New)
Manning & Napier Advisors, Inc 485,810 sh (+21.61%)
PRIMECAP Management 10,954,900 sh (+0.54%)
Columbia Wanger 5,155,000 sh (-22.01%)
» More
Q4 2014

SGEN Guru Trades in Q4 2014

PRIMECAP Management 11,178,050 sh (+2.04%)
Manning & Napier Advisors, Inc 485,810 sh (unchged)
Ray Dalio Sold Out
Columbia Wanger Sold Out
Columbia Wanger 4,474,100 sh (-13.21%)
» More
Q1 2015

SGEN Guru Trades in Q1 2015

PRIMECAP Management 11,836,575 sh (+5.89%)
Manning & Napier Advisors, Inc 492,690 sh (+1.42%)
Columbia Wanger 3,408,200 sh (-23.82%)
» More
Q2 2015

SGEN Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 252,470 sh (-48.76%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 27.43
SGEN's P/B is ranked lower than
94% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. SGEN: 27.43 )
Ranked among companies with meaningful P/B only.
SGEN' s 10-Year P/B Range
Min: 1.74  Med: 8.44 Max: 30.72
Current: 27.43
1.74
30.72
P/S 19.02
SGEN's P/S is ranked lower than
63% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. SGEN: 19.02 )
Ranked among companies with meaningful P/S only.
SGEN' s 10-Year P/S Range
Min: 9.98  Med: 20.52 Max: 45.83
Current: 19.02
9.98
45.83
Current Ratio 3.10
SGEN's Current Ratio is ranked lower than
61% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. SGEN: 3.10 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s 10-Year Current Ratio Range
Min: 2.75  Med: 5.23 Max: 30.03
Current: 3.1
2.75
30.03
Quick Ratio 2.76
SGEN's Quick Ratio is ranked lower than
62% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SGEN: 2.76 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s 10-Year Quick Ratio Range
Min: 2.75  Med: 5.02 Max: 30.03
Current: 2.76
2.75
30.03
Days Inventory 428.00
SGEN's Days Inventory is ranked lower than
94% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. SGEN: 428.00 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s 10-Year Days Inventory Range
Min: 442.93  Med: 557.12 Max: 639.76
Current: 428
442.93
639.76
Days Sales Outstanding 60.20
SGEN's Days Sales Outstanding is ranked higher than
51% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SGEN: 60.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s 10-Year Days Sales Outstanding Range
Min: 25.55  Med: 80.45 Max: 1028.64
Current: 60.2
25.55
1028.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 101.06
SGEN's Price/Net Cash is ranked lower than
95% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. SGEN: 101.06 )
Ranked among companies with meaningful Price/Net Cash only.
SGEN' s 10-Year Price/Net Cash Range
Min: 2.12  Med: 10.58 Max: 75.21
Current: 101.06
2.12
75.21
Price/Net Current Asset Value 37.11
SGEN's Price/Net Current Asset Value is ranked lower than
90% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. SGEN: 37.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGEN' s 10-Year Price/Net Current Asset Value Range
Min: 2.09  Med: 9.59 Max: 447
Current: 37.11
2.09
447
Price/Tangible Book 28.27
SGEN's Price/Tangible Book is ranked lower than
91% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. SGEN: 28.27 )
Ranked among companies with meaningful Price/Tangible Book only.
SGEN' s 10-Year Price/Tangible Book Range
Min: 1.78  Med: 5.55 Max: 24.23
Current: 28.27
1.78
24.23
Price/Median PS Value 0.96
SGEN's Price/Median PS Value is ranked higher than
63% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. SGEN: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
SGEN' s 10-Year Price/Median PS Value Range
Min: 0.5  Med: 1.15 Max: 27.14
Current: 0.96
0.5
27.14
Earnings Yield (Greenblatt) (%) -1.50
SGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SGEN: -1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.3  Med: 0.00 Max: 0
Current: -1.5
-2.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. In August 2011, the U.S. Food and Drug Administration, or FDA, granted accelerated approval of ADCETRIS, or brentuximab vedotin, in two indications; the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant, or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma, or sALCL, after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Companys proprietary technology. The Company collaborated with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS. The Company has a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy in patients with Hodgkin lymphoma and sALCL and other CD30-positive malignancies. In addition, it has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
Comment for Companies Ranked by Business Predictability Jan 03 2013 
Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 

More From Other Websites
Cramer: Receptos perfect fit for Celgene Jul 15 2015
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
Growing Seattle Genetics tests cancer therapy for treatment of lupus Jul 09 2015
Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus... Jul 09 2015
Seattle Genetics Initiates Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Systemic Lupus... Jul 09 2015
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial... Jul 08 2015
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2015 Financial... Jul 08 2015
WEEKEND VIDEO: Sentiment, Stocks and more Jul 03 2015
Edited Transcript of SGEN earnings conference call or presentation 30-Apr-15 8:30pm GMT Jun 30 2015
Collaborations make Seattle Genetics a safer way to play biotech Jun 24 2015
SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers Jun 22 2015
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the... Jun 17 2015
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the... Jun 17 2015
The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE... Jun 11 2015
Biotech Stock Roundup: FDA Panel Recommends Regeneron's Praluent, SAGE Gains on Data - Analyst Blog Jun 10 2015
A cancer cure that excites investors: A look at Seattle's immunotherapy deals of 2015 Jun 09 2015
Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog Jun 09 2015
Seattle Genetics pays Boston-area company $25M to grow immunotherapy portfolio Jun 09 2015
Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration Jun 08 2015
Seattle Genetics and Unum Therapeutics Enter into Strategic Cancer Immunotherapy Collaboration Jun 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK